A Phase II Study of Capecitabine, Oxaliplatin (XELOX) and Bevacizumab for patient with high-risk Upper Rectal Cancer as Neo-Adjuvant chemotherapy.
Not Applicable
Completed
- Conditions
- pper rectal cancer
- Registration Number
- JPRN-UMIN000015765
- Lead Sponsor
- Cancer Institute Hospital of Japanese Foundation for Cancer Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
Not provided
Exclusion Criteria
1. Malignant coelomic fluid. 2. Multiple primary cancer within 5 years. 3. History of intrapelvic irradiation. 4. Clinically significant complication (heart failure, interstitial lung disease or pulmonary fibrosis, uncontrolled diabetes, renal failure, liver failure, etc.) 5. History of the serious hypersensitivity for any agents. 6. Uncontrolled diarrhea. 7. Evidence of peripheral sensory neuropathy. 8. Uncontrolled Active infection. 9. Other conditions not suitable for this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method